Biofrontera AG | B8F Annual Report & Investor Relations Data
ISIN
DE0006046113
Ticker
B8F
Sector
Industry
Country
Germany
Year Founded
1997
ISIN
DE0006046113
Ticker
B8F
Sector
Industry
Country
Germany
Year Founded
1997
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin.
The company's lead product is the combination of Ameluz;, a topical prescription drug, and medical device BF-RhodoLED; for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz; has been marketed in the EU since 2012 and in the United States since May 2016.
Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Luebbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.
149
Worldwide
| Type | Document | Details | Language | Filing Date | File Number |
|---|
Access comprehensive European stock market filings data through a single, powerful API.
1,5M+
filings covered
18
European countries
30min
max latency
1 API
for all filings
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 24.03.2023 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 7,366.00 |
| 24.03.2023 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 381.00 |
| 20.03.2023 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 7,503.16 |
| 13.03.2023 | NEON Equity AG | Close relation | Buy | EUR 30,627.00 |
| 13.03.2023 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 6,290.31 |
| 13.03.2023 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 635.00 |
| 13.03.2023 | TO Holding 1 GmbH | Close relation | Buy | EUR 575.00 |
| 10.03.2023 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 6,718.30 |
| 08.03.2023 | Adenauer, Dr. Sven-Georg | Other | Buy | EUR 140,000.00 |
| 06.03.2023 | Deutsche Balaton Aktiengesellschaft | Close relation | Buy | EUR 152.40 |
We currently don't have information about the management or supervisory board for this company. This information will be updated as soon as it becomes available.
DE0006046113
391200D6GFSVFGFQTL13
ICF Bank AG
VSC
Sector
Health Care
Country
Germany
ISIN
DE000A3E5C40
Founded
1997
4SC focuses on the development of novel small molecule drugs that target key mechanisms of cancer development, such as histone …
ABNX
Sector
Health Care
Country
France
ISIN
FR0012616852
Founded
ABIONYX Pharma is a new-generation biotech company that aims to contribute to health through innovative therapies in indications where there …
ABLI
Sector
Health Care
Country
Sweden
ISIN
SE0002575340
Founded
2000
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when …
AB
Sector
Health Care
Country
France
ISIN
FR0010557264
Founded
2001
AB Science is a late-clinical-stage French company founded in 2001 by a team of scientists with the goal of developing …
ALACT
Sector
Health Care
Country
France
ISIN
FR0014005OJ5
Founded
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of …
ACTI
Sector
Health Care
Country
Sweden
ISIN
SE0001137985
Founded
1998
Active Biotech develops pharmaceutical products within medical areas where the immune system is of significant importance, including cancer and inflammatory …